Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Last year's massive gain was only the beginning of the story.

Here's Why This Top Stock Is a Buy on the Dip

NVAX stock is in danger of repeating prior failures. The window of opportunity is closing and it's a movie investors have seen before.

Novavax Window of Opportunity Is Closing Fast

Bionano Genomics

Marathon Digital Holdings

Plug Power

Riot Blockchain

Are these popular momentum stocks too cheap to ignore or blatant value traps?

5 Risky Stocks With 138% to 216% Upside, According to Wall Street

The shares of Novavax, Inc. (NASDAQ: NVAX) have received a price target decrease from $317 to $294 by H.C. Wainwright.

Novavax (NVAX) Stock: $294 Target By H.C. Wainwright

GameStop

With gains ranging from 450% to nearly 3,000%, these big companies have been unstoppable.

4 Large-Cap Stocks That Turned $200,000 Into $1 Million (or More) in 1 Year

With strong liquidity and a massive vaccine market, Novavax is perfectly positioned in the industry. NVAX stock is a good buy in the dip.

The Dip In Novavax Is The Perfect Buying Opportunity

If Novavax is successful, it could generate billions.

This Is Novavax's Biggest Weakness Right Now -- and Here's How the Company May Overcome It

Human trials of the combination vaccine are expected to start later this year.

Novavax Reports Positive Data From Animal Trial of Its COVID-19/Flu Combo Shot

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower by 3.7% at $133.05 after JPMorgan downgraded the stock from Overweight to Neutral and lowered its price target from $285 to $161 per share. Novavax is a biotechnology company that develops vaccines.

Why Novavax Is Moving Today

The stock price of Novavax has seen a large 18% drop in just five trading sessions. The decline was driven partly due to the company's announcement that it doesn't plan to file for authorization for its Covid-19 vaccine in the U.S. and Europe until Q3 of this year.

Should You Buy Novavax Stock After A Large 18% Fall In 5 Days?

The European Commission president has provided some hints that a supply agreement with Novavax could be on the way.

Why Novavax Could Beat Moderna in Europe After Pfizer's Huge EU Vaccine Deal

An analyst's price target cut reflected an uncomfortable new reality for the biotech.

Why Novavax Stock Sank Again on Tuesday

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

The patent waiver matter will likely prove to be a "nonissue," while NVAX stock has many upcoming, positive catalysts. The post Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness appeared first on InvestorPlace.

Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness

Novavax shares on Tuesday sharply extended losses during a two-day rout after the biotech company delayed seeking approval for its COVID-19 vaccine from three regulators, including the Food and Drug Administration. The shares came under pressure on Monday following a Washington Post report that the company would delay filing for emergency use authorization for its experimental coronavirus vaccine in the US until June at the earliest, because of manufacturing issues. During a Monday conference call, Novavax reportedly said it expects to submit its vaccine to regulators in the US, the UK and the European Union in the third quarter.

Novavax extends 2-day loss to 31% as the biotech firm delays seeking emergency authorization for its COVID-19 vaccine (NVAX, RUT)

Novavax Inc (NASDAQ: NVAX) delayed ramping up COVID-19 vaccine production again on Monday and said it was unlikely to seek regulatory approval for its shot in Europe, UK, and the United States until Q3 of 2021. Shares of the company slid about 7% in premarket trading on Tuesday.

Here's why Novavax stock fell again on Tuesday morning

Moderna

The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NASDAQ: AZN), Novavax Inc (NASDAQ: NVAX), Halberd Corp (OTC US: HALB), and Johnson & Johnson (NYSE: JNJ). The pandemic is under control.

New Approaches to Covid-19 Treatment Enter the Picture

Vaccine stocks had a rough week, with Novavax stock down almost -25%, Moderna down by about -9%, and Pfizer stock up by just about 2% despite posting a very solid set of first-quarter results. The decline is largely driven by the Biden administration's support of the temporary waiver of.

Moderna And Novavax Stocks Fall On IP Waiver Concerns, But Sell Off Is Overdone

AstraZeneca

BioNTech SE

Johnson & Johnson

Pfizer

The government is having issues with giving away its excess supply.

How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers?

It had nothing to do with the company's financial performance.

Here's the Only Thing in Novavax's Q1 Update That Investors Cared About

Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.

The Wall Street Journal: Novavax delays its COVID-19 vaccine timeline

Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates

The company's latest coronavirus vaccine news produced an unpleasant side effect.

Why Novavax Tanked Monday

Novavax Inc said on Monday it will ramp up production of its COVID-19 vaccine slower than it had previously anticipated and does not expect to file for regulatory approval in the United States, Britain or Europe until the third quarter of 2021.

Novavax again delays COVID-19 vaccine production timeline, shares fall

Shares of Novavax (NASDAQ:NVAX) rose after the company reported Q1 results. Quarterly Results Earnings per share were down 425.86% over the past year to ($3.05), which beat the estimate of ($3.60).

News for Novavax Stock (NVAX)